REFERENCES

1. Ting L, Ren C, Manali W, Ligang Z, Ximeng W, Liang F. Optimized preparation and evaluation of indomethacin transdermal patch. Asian J Pharm Sci 2007; 2(6): 249-259.
2. Ren C, Liang F, Lei L, Quang W, Sihai L, LiGang Z, Zhonggui H. Design and *invivo* evaluation of indapamide transdermal patch. Int J Pharm 2009; 370:129-35.
3. Mohd A, Asgar A, Yasmin S, Dubey K, Abdul NK, Kollapa PK. *Invivo* characterization of monolithic matrix type transdermal drug delivery systems of pinacidil monohydrate: A technical note AAPS PharmSci Tech 2006; 7(1): E1-E4.
4. Zhao L, Li Y, Fang L, He Z, Liu X, Wang L, Xu Y, Ren C. Transdermal delivery of Tolerodine by O-acylmenthol: *In vitro*/*In vivo* correlation. Int J Pharm 2009; 374: 73-81.
5. Thacharodi D, Rao PK. Development and *In vitro* evaluation of chitosan-based transdermal drug delivery systems for the controlled delivery of propranolol hydrochloride. Biomaterials 1995; 16(2): 145-148.
6. Joseph RR, Vincent HL. Controlled drug delivery fundamentals and applications.2nd ed. Revised and Expanded: Lee. Marcel Dekker, INC; 2005: 524.
7. Padula C, Nicoli S, Colombo P, Santi P. Single-layer transdermal film containing lidocaine: modulation of drug release. Eur J Pharm & Biopharm 2007: 422-428.
8. Gale R, Hunt J, Prevo ME. Transdermal drug delivery, passive. Encyclopedia of controlled drug delivery, Vol 2: 975-990. Edited by Edith Mathiowitz; Wiley-Interscience publication: copyright 1999 by John Wiley & Sons, Inc.
9. Cantor AS, Wirtanen DJ. Novel acrylate adhesives for transdermal drug delivery. Pharma Tech 2002(1): 28-38.
10. Nitti VW, Sanders S, Staskin DR., Dmochowski RR., Sand PK, MacDiarmid Scott, Maibach HI. Transdermal delivery of drugs for urologic applications: basic principles and applications. J urology 2006; 67(4): 657-664.
11. Kakubari I, Shinkai N, Kawakami J, Uruno A, Takayasuka T, Yamauchi H, Takayama S, Takayama K. Formulation and Evaluation of Ethylene-vinyl acetate Copolymer Matrix Patches containing Formoterol fumarate. Bio Pharm Bull 2006; 29(3): 513-516.

12. Tripathi KD. Insulin, oral hypoglycemics and glucagons, in: Essentials of Medical Pharmacology. 6th edition, Jaypee Brothers Medical Publishers (P) Ltd., New Delhi, 2008: 235.
13. Dornhorst Anne. Insulinotropic meglitinide analogues; new drug classes. The Lancet 2001; 358: 1709-1716.
14. Ambavane V, Patil R, Aina SS. Repaglinide: A short acting insulin secretogogue for post prandial hyperglycaemia. J Postgrad Med 2002; 48: 246-248.
15. Repaglinide, The free encyclopedia : http://en.wikipedia.org/wiki/Repaglinide
16. Chein YW. Eds. Yie W. Chein-Transdermal Drug Delivery Systems. 2nd Ed. Marcel Dekker, INC; 1992: 301.
17. Nicoli S, Colombo P, Santi P. Release and permeation kinetics of Caffeine from bioadhesive transdermal films. The AAPS Journal 2005; 7 (1): E218-E223.
18. Mehdizadeh A, Toliate T, Rouini MR, Abashzadeh S, Dorkoosh F. Design and *In vitro* evaluation of new drug-in-adhesive formulations of Fentanyl transdermal patches. Acta Pharm 2004; 54: 301-317.
19. Tan HS, Pfister WR. Pressure-sensitive adhesives for transdermal drug delivery systems. PSTT 1999; 2(2): 60-69.
20. Wokovich AM, Prodduturi S, Doub WH., Hussain AS, Buhse LF. Transdermal drug delivery system adhesion as a critical safety, efficacy and quality attribute. Euro J pharm and Bio pharm 2006; 64: 1-8.
21. Williams AC, Barry BW. Penetration enhancers. Adv Drug Del Rev 2004; (56): 603-618.
22. Charoo NA, Shamsher AA, Kohli K, Pillai K, Rahman Z. Improvement in bioavailability of transdermally applied flurbiprofen using tulsi (Ocimum sanctum) and turpentine oil. J colloids and surfaces B: Biointerfaces 2008; (65): 300-307.
23. Gandhimathi M, Ravi TK, Renu SK. Determination of Repaglinide in Pharmaceutical Formulations by HPLC with UV Detection. Analytical Sciences 2003; 19: 1675-1677.
24. Gupta GD, Patel P, Chaudhary A, Tanwar YS. *In-vitro* permeation of repaglinide from polymeric membrane systems across human cadaver system. Priory Medical Journals, January 1995. www.priory.com/index.html.
25. Jain SK, Awasthi AM, Jain NK, Agrawal GP. Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: Preparation and *in vitro* characterization. J Contr Rel 2005; 107: 300-309.

26. Mutalik S, Udupa N. Pharmacological evaluation of membrane-moderated transdermal system of glipizide. Clin. Exp. Pharmacol. Physiol. 2006; 33: 17-26.
27. Mutalik S, Udupa N, Kumar S, Agarwal S, Subramanian G, Ranjith AK. Glipizide matrix transdermal systems for diabetes mellitus: Preparation, *in vitro* and preclinical studies. Life Sciences 2006; 79: 1568-1577.
28. Zoran M, Vesna G. Ionization, lipophilicity and solubility properties of repaglinide. J Pharm and Biomed Anal 2006; 41: 866-871.
29. Bijaya G, Reddy HL, Kulkarni RV, Khanam J. Comparison of skin permeability of drugs in mice and human cadaver skin. Indian J Exp Bio 2000; (38): 42-45.
30. Ekapol L, Kraisri U. Preparation and evaluation of diltiazem hydrochloride diffusion-controlled transdermal delivery system. AAPS PharmSciTech 2008; 9(2): 464-470.
31. Ubaidulla U, Reddy M.S, Ruckmani K, Ahmad FJ, Khar RK. Transdermal therapeutic system of carvedilol: Effect of hydrophilic and hydrophobic matrix on *in vitro* and *in vivo* characteristics. AAPS PharmSciTech 2007; 8 (1): E1-E8.
32. Mutalik S, Udupa N. Glibenclamide transdermal patches: Physicochemical, Pharmacodynamic, and Pharmacokinetic evaluations. J Pharm Sci 2004; 93(6): 1577-1594.
33. Sridevi S, Chary MG, Krishna DR, Diwan PV. Pharmacodynamic evaluation of transdermal drug delivery system of glibenclamide in rats. Indian J Pharmacol 2000; 32: 309-312.
34. Purvis Troy, Mattucci ME, Crisp MT, Johnston KP, Williams RO. Rapidly dissolving repaglinide powders produced by the Ultra-Rapid Freezing process. AAPS PharmSciTech 2007; 8(3): E1-E9.
35. Trotta M, Peer Elena, Carlotti ME, Gallarate M. Deformable liposomes for dermal administration of Methotrexate. Int J Pharm 2004; 270: 119-125.
36. Barhate SD, Patel MM, Sharma AS, Nerkar P, Shankhpal G. Formulation and evaluation of transdermal drug delivery system of Carvedilol. J Pharm Res 2009, 2(4), 663-665.
37. Mehdizadeh A, Toliate T, Rouini MR, Abashzadeh S, Dorkoosh F. Design and *in vitro* evaluation of new drug-in-adhesive formulation of Fentanyl transdermal patches. Acta Pharm 2004; 54: 301-317

38. Wokovich AM, Prodduturi S, Doub WH, Hussain AS, Buhse LF. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute. Euro J pharm and Bio pharm 2006; (64): 1-8.
39. Shivhare UD, Dorlikar VP, Bhusari KP, Mathur VB, Mirani BN. Effect of Polymeric Compositions on Pharmacotechnical Properties of Carvedilol Transdermal Film. Int J Pharm Sci and Nanotech, 2 (1): April – June 2009
40. Jain A, Ghosh B, Rajgor N, Desai BG. Passive and iontophoretic permeation of glipizide. Euro J pharm and Bio pharm 2008; 69(3): 958-963.
41. Ubaidulla U, Sentil KB, Ramu P, Sreenivasa PP, Upendra KS, Effect of iontophoresis and permeation enhancer on Carvedilol from transdermal films. Indian Pharm. ISSN 0972-7914.
42. Tashiro Y, Sami m, Shichibe S, Kato Y, Hayakawa E, Itoh K. Effect of lipophilicity on *in-vivo* iontophoretic delivery. II. Beta blockers, Bio Pharm Bull. 2001; 24: 671-677.